Product image of Nintedanib Accordpharma (Nintedanib) supplied by GNH India

Nintedanib Accordpharma

Active Ingredient:
Nintedanib
Origin:
EU

Nintedanib Accordpharma (Nintedanib)

Nintedanib, the active ingredient in Nintedanib Accordpharma, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and as part of combination therapy for non‑small cell lung cancer.

GNH India supplies Nintedanib Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nintedanib acts on fibrotic and oncogenic pathways, providing therapeutic benefit in several pulmonary and oncologic conditions.

  • Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function.
  • Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delays worsening.
  • Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition when used with other anticancer agents.

How It Works

  • Nintedanib inhibits multiple receptor tyrosine kinases—including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet‑derived growth factor receptors (PDGFR). By blocking these pathways, it reduces fibroblast proliferation, angiogenesis, and the fibrotic remodeling that underlies progressive lung disease and supports tumor vascularization.

Side Effects

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Decreased appetite
  • Vomiting
  • Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects

  • Hepatic failure
  • Severe bleeding events
  • Cardiovascular complications (e.g., myocardial infarction)
  • Gastrointestinal perforation
  • Severe infections
  • Pneumothorax

Precautions & Warnings

When prescribing Nintedanib, clinicians should consider several safety precautions.

  • Renal impairment: monitor renal function and adjust therapy as needed.
  • Hepatic dysfunction: perform baseline and periodic liver‑function tests.
  • Bleeding risk: avoid concomitant use of strong anticoagulants unless benefits outweigh risks.
  • Pregnancy: use only if potential benefit justifies potential fetal risk.
  • Cardiovascular disease: assess baseline risk and monitor for cardiac events.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Nintedanib can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure.
  • Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding.
  • High‑dose aspirin or other antiplatelet agents: elevated bleeding potential.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
  • P‑gp inhibitors (e.g., verapamil): could raise plasma concentrations.
  • Diuretics: monitor for dehydration and renal function.

Frequently Asked Questions

Nintedanib Accordpharma is prescribed for idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and as part of combination therapy for non‑small cell lung cancer. In each case, it targets pathways that drive fibrosis or tumor growth, helping to slow disease progression.

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR, and PDGFR—thereby inhibiting fibroblast proliferation, new blood‑vessel formation, and the fibrotic processes that contribute to lung scarring and tumor angiogenesis.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, weight, organ function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of Nintedanib in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nintedanib differs from other antifibrotics such as pirfenidone by targeting a broader range of tyrosine‑kinase receptors (VEGFR, FGFR, PDGFR). This multi‑target approach can provide additional benefit in certain fibrotic lung diseases, though individual response and safety profiles vary and should be evaluated by the treating physician.

Store the product at ambient temperature, below 25 °C, in the original packaging. Keep it away from moisture, direct sunlight, and excessive heat to maintain stability and potency.

Nintedanib Accordpharma is taken orally, usually as whole tablets swallowed with water. It is typically taken with food to reduce gastrointestinal discomfort, but patients should follow the specific instructions provided by their healthcare professional.

Serious risks include liver injury, severe bleeding, cardiovascular events such as myocardial infarction, gastrointestinal perforation, and rare cases of pneumothorax. Patients should be monitored regularly for signs of these complications and report any concerning symptoms promptly.

Nintedanib should be avoided in patients with known hypersensitivity to the drug, severe hepatic impairment, uncontrolled bleeding disorders, or those who are pregnant unless the benefit justifies the risk. Clinicians must also assess renal function and cardiovascular status before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nintedanib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT